Global COVID-19 vaccination matters now and for the future

Recently, I joined a panel at the Aspen Security Forum to discuss how we can best get vaccines in arms around the globe as we fight COVID-19. As I noted during my remarks, the world is more...
Read More
Guest post: Congress should not put future innovation at risk

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...
Read More
What is missing in the current drug pricing plan

A recent congressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important...
Read More
Insurance design barriers can impact patient adherence and can lead to poor health outcomes

According to our inaugural Patient Experience Survey (PES), insurance design can jeopardize patients’ health due to access barriers to medicines.
Read More
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke with STAT’s Matthew Herper to discuss the many unintended consequences expected from the latest drug pricing...
Read More
Making medicines more affordable: Sharing savings at the pharmacy counter

Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...
Read More
Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and other...
Read More
Three things to know about so-called Medicare negotiation polling

As policymakers continue to push partisan drug pricing proposals, several polls misrepresenting voter opinion have been circulated to try and justify these flawed policies. These polls fail to...
Read More
In the current health care debate, Congress has lost sight of what matters to U.S. voters

For months Congress has been debating massive changes to the nation’s social safety net, one of which is the highly popular Medicare prescription drug benefit. Unfortunately, much of what is being...
Read More
Announcing CAREs Grant Round 4

Medicines can be critical to treating, managing, and sometimes curing illnesses, thereby offering an effective tool to improve health outcomes and reduce health disparities. However, numerous studies...
Read More
Making medicines more affordable: Modernizing Medicare

Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...
Read More
Understanding breakthrough COVID-19 infections

The biopharmaceutical industry continues to work around the clock to research, develop and manufacture vaccines and therapeutics to prevent and treat COVID-19. Already, we’ve made unprecedented...
Read More
Making Medicines More Affordable: Making coupons count

Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...
Read More
What they are saying: Government price setting for medicines is not the answer

America’s biopharmaceutical companies continue to voice the dangers of current proposals in Washington that would allow the government to set prices for medicines. While it’s being called government...
Read More
Fact Check: Do contract pharmacies help patients access 340B medicines? No.

Over the years, there has been repeated acknowledgement that the 340B program is often not supporting the patients it was intended to help. (If you need a reminder, check out this piece in the New...
Read More
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

A new report from NDP Analytics showcases how innovation is the lifeblood of economic growth in the United States and that intellectual property (IP) protections are a crucial driver for high rates...
Read More